a b s t r a c t Natural killer (NK) cells are effector lymphocytes that are under clinical investigation for the adoptive immunotherapy of hematologic malignancies, especially acute myeloid leukemia. Recent work in mice has identified innate memory-like properties of NK cells. Human NK cells also exhibit memory-like properties, and cytokine-induced memory-like (CIML) NK cells are generated via brief preactivation with IL-12, IL-15, and IL-18, which later exhibit enhanced functionality upon restimulation. However, the optimal cytokine receptors and signals for maintenance of enhanced function and homeostasis after preactivation remain unclear. Here, we show that IL-12, IL-15, and IL-18 preactivation induces a rapid and prolonged expression of CD25, resulting in a functional high-affinity IL-2 receptor (IL-2Rabg) that confers responsiveness to picomolar concentrations of IL-2. The expression of CD25 correlated with STAT5 phosphorylation in response to picomolar concentrations of IL-2, indicating the presence of a signal-competent IL-2Rabg. Furthermore, picomolar concentrations of IL-2 acted synergistically with IL-12 to costimulate IFN-g production by preactivated NK cells, an effect that was CD25 dependent. Picomolar concentrations of IL-2 also enhanced NK cell proliferation and cytotoxicity via the IL-2Rabg. Further, after adoptive transfer into immunodeficient NOD-SCID-g c À/À mice, human cytokineepreactivated NK cells expand preferentially in response to exogenous IL-2. Collectively, these data demonstrate that human CIML NK cells respond to IL-2 via IL-2Rabg with enhanced survival and functionality, and they provide additional rationale for immunotherapeutic strategies that include brief cytokine preactivation before adoptive NK cell transfer, followed by low-dose IL-2 therapy.
INTRODUCTION
Natural killer (NK) cells are a subset of innate lymphoid cells critical for host antiviral defense and mediate antitumor immunity [1] [2] [3] [4] [5] . NK cells are of clinical interest and are being explored as antitumor effectors in the allogeneic hematopoietic stem cell transplantation (HSCT) setting as well as an adoptive cellular therapy of hematologic disease [6] [7] [8] . Initial reports in the MHC-haploidentical transplantation setting indicated that NK cells may be harnessed for graft-versusleukemia effects in the absence of graft-versus-host disease [9] . Subsequent studies have investigated the molecular basis of killer-cell immunoglobulin-like receptor genetics and their MHC class I ligands on NK cell functional responses and outcomes after allogeneic HSCT [10] [11] [12] . These studies highlight the importance of integrating new advances in basic NK cell biology, such as education and licensing, when applying NK cells as therapeutics in the HSCT or adoptive transfer setting.
NK cells are traditionally classified as innate immune lymphocytes because they do not rearrange germline DNA to form a dominant clonal activation receptor, distinct from T and B cells. However, this paradigm has recently been challenged by several groups identifying innate memory mediated by mouse NK cells [13] in the setting of hapten-based sensitization [14] , viral (murine cytomegalovirus [MCMV] ) infection [15] , and after cytokine activation with IL-12, IL-15, and IL-18 [16] . Notably, NK cell memory that occurs after MCMV infection depends on proinflammatory cytokines [17] , suggesting a common mechanistic link between virus-and cytokine-induced NK cell memory. Studies in humans have also shown that viral infection, in particular, human cytomegalovirus, results in imprinting on the NK cell compartment via altering the expression patterns of NKG2C and killer-cell immunoglobulin-like receptors that correlate with NK cell functional status. These studies include cytomegalovirus reactivation after solid organ transplantation and HSCT, which may correlate with murine virus-induced memory NK cells [18, 19] . Human NK cell memory-like responses have been directly demonstrated in vitro after cytokine activation with IL-12, IL-15, and IL-18 [20] . A brief (16 hour) preactivation with IL-12, IL-15, and IL-18, followed by rest in vitro for 1 to 6 weeks, resulted in enhanced functionality, including IFN-g production after restimulation with cytokines or exposure to leukemia targets. This enhanced functionality extended to both primary NK cell subsets present in peripheral blood (CD56 bright and CD56 dim ). IL-15 was used as a survival cytokine during the in vitro rest period based on prior studies; however, additional cytokines that may contribute to the homeostasis and enhanced function of such cytokine-induced memory-like (CIML) NK cells have not been reported. Recent work has shown that murine IL-12, IL-15, and IL-18 preactivated NK cells have an enhanced ability to control tumor cell line challenge, which in vivo in mice required T cellederived IL-2 [21] . We, therefore, investigated the expression of CD25, a key component required to form the high-affinity heterotrimeric IL-2Rabg on human NK cells briefly activated with combinations of IL-12, IL-15, and IL-18. NK cells constitutively express 2 components of the high-affinity IL-2R: the IL-2/15Rb and g c , which form an intermediate affinity heterodimer that transduces signals in the presence of nanomolar concentrations of IL-2 or IL-15. In contrast, the heterotrimeric highaffinity IL-2Rabg (including IL-2Ra, CD25) is ligated by picomolar concentrations of IL-2, and thus CD25 expression dictates high-affinity IL-2 binding on NK cells [22, 23] 
MATERIALS AND METHODS

Reagents
The following antihuman mAbs were used: Beckman Coulter (Brea, California): CD56(N901), CD3(UCHT1); BD (Franklin Lakes, NJ): CD16(3G8), IFN-g(B27), CD25(M-A251), pSTAT5(pY694); purified anti-CD25 (B-B10, eBioscience, San Diego, CA) or isotype IgG1k (Biolegend, San Diego, CA). The following endotoxin-free cytokines were used: rhIL-2 (Chiron, Emeryville, CA); rhIL-15 (CellGenix, Freiburg, Germany); rhIL-12, rhIL-18 (Peprotech, Rocky Hill, NJ). The K562 (ATCC, Manassas, VA) cell line was maintained in RPMI-1640 plus 10% FCS and supplements FCS and supplements [20] .
NK Cell Purification and Cell Culture
Anonymous human platelet apheresis donor peripheral blood mononuclear cells (PBMCs) were isolated by ficoll centrifugation. NK cells were purified to >95% CD56 þ CD3-purity using Rosettesep enrichment (StemCell Technologies, Vancouver, Canada) as described [20] . In some experiments, CD56 dim NK cells were isolated by flow cytometric sorting (>99% pure). NK cells were cultured at 5 Â 10 6 /mL in complete RPMI-1640 media (Hyclone, Logan, UT) with 10% human AB serum (Sigma, Saint Louis, MO) and supplements [20] .
Assays to Assess CD25 Expression and Functions
Purified NK cells were preactivated for 16 hours with individual cytokines or combinations for 16 hours, washed 3 times, and replated in IL-15 (1 ng/mL) for 2 or 6 additional days. At each time point, cells were harvested and assessed for CD25 expression by flow cytometry. For pSTAT5 experiments, cells were stimulated with varying concentrations of IL-2 for 15 minutes and then stained for pSTAT5 as described [20] . In some experiments, cells were preincubated for 1 hour at 37 C with either an isotype or anti-CD25 antibody (10 mg/mL). Preactivated cells were restimulated after 3 days of in vitro culture with varying concentrations of IL-2, with or without IL-12. Cells were incubated for 6 hours in the presence of BFA/ monensin (BD) and assayed for intracellular IFN-g [20] .
Flow Cytometric Analysis
Cell staining was performed as described [20, 27] , and data were acquired on a Gallios flow cytometer (Beckman Coulter) and analyzed using FlowJo (TreeStar, Ashland, OR) or Kaluza (Beckman Coulter) software. Phospho-STAT5 flow cytometry assays were performed following the manufacturer's instructions (BD).
Flow-Based Killing Assay
Sorted CD56 dim NK cells were preactivated for 16 hours, washed 3 times, and then cultured in cytokine-free media for 2 days. Cells were then cultured for an additional 24 hours, with or without the addition of IL-2, before harvesting for use as effectors in cytotoxicity assays. Flow-based killing assays were performed by coincubation with CFSE-labeled K562 cells for 4 hours and assaying 7-AAD uptake as described [28] . Spontaneous background K562 death (no effector control wells) was subtracted to yield percent specific killing, and in all cases was less than 5%. Flow-based killing assay results consistently correlate with 51 Cr release assays and provide a direct method to count individual dead target cells [28, 29] .
In Vitro Proliferation and Survival Assays CFSE-labeled, sorted CD56 dim NK cells were preactivated and cultured in IL-2econtaining media, with media and cytokine changes every other day. On day 7, cells were harvested and assessed for CFSE-dilution staining or 7-AAD by flow cytometry.
Human NK Cell Xenograft Experiments
Purified human NK cells were preactivated with IL-12, IL-15, and IL-18 or 1 ng/mL IL-15 alone (control) for 16 hours and washed 3 times, and then equivalent numbers of control or CIML NK cells from the same donor were transferred retro-orbitally into groups of NSG mice (3 Â 10 6 /mouse to 8 Â 10 6 /mouse). Mice were injected with rhIL-2 (75,000 IU/mouse) every other day Â 3 doses. On day 7, mice were sacrificed and human cells were identified with human CD45 and CD56/CD16 expression, and all human CD45þ cells were NK cells. The relative abundance of NK cells was determined by calculating the ratio of mouse CD45 to human CD45 positive cells in the spleen, to control for variable absolute leukocyte numbers in different NSG mice.
Statistical Analysis
Statistical comparisons were performed using Student t-test or ANOVA (*P < .05; **P < .005; ***P < .0005), where appropriate.
RESULTS
Induction of CD25 on IL-12, IL-15, and IL-18 Preactivated Human NK Cells
We hypothesized that combinations of IL-12, IL-15, and IL-18 stimulate NK cells to express CD25, thereby acquiring responsiveness to low concentrations of IL-2. To test this premise, cytokines known to bind to constitutively expressed cytokine receptors on resting NK cells were evaluated for the ability to induce cell surface CD25 expression. Purified human NK cells were cultured overnight in IL-2, IL-12, IL-15, IL-18, or combinations of these cytokines. Low-dose IL-15 (LD15) was used as a control to maintain survival. At 16 hours, all cytokines tested, with the exception of LD15, resulted in increased expression of CD25 on both CD56 [20] . We also observed increased expression of CD25 by both CD56 bright and CD56 dim NK cells, but notably, the MFI increase in CD56 dim NK equaled or exceeded that of CD56 bright NK cells in every cytokine condition tested (data not shown). Similar results were seen with NK cells cultured within PBMC (Supplemental Figure 1 ). Because CD25 is not expressed in freshly isolated CD56 dim NK cells, and is at a low density on CD56 bright NK cells, we evaluated whether the mechanism of induction of CD25 was at the IL2RA (CD25) mRNA level.
There was a marked increase in IL2RA mRNA in NK cells after stimulation (Supplemental Figure 2) , suggesting that the mechanism of increased CD25 expression is primarily to enhance transcription or stability of CD25 mRNA. Thus, NK cells preactivated with the combination of cytokines that induce CIML NK cells also express CD25 for a prolonged time period, which may facilitate responsiveness to low concentrations of IL-2.
CD25 Induced on NK Cells by Cytokines Results in a
Signal-Competent IL-2Rabg CD25 associates with the intermediate-affinity IL-2Rbg subunits to form the high-affinity heterotrimeric IL-2Rabg [22, 30] . In response to ligation with IL-2, this complex signals through the IL-2Rbg chains, resulting in phosphorylation of STAT5 [22, 23] . We, therefore, evaluated whether cytokineactivated NK cells exhibited increased phospho-STAT5 when stimulated with picomolar concentrations of IL-2, which selectively ligate the high-affinity IL-2Rabg. In these experiments, we focused on preactivation cytokine combinations that result in CIML NK cells and the most pronounced induction of CD25: IL-15 plus IL-18 (also allowing assessment of IL-12-independent responses), or IL-12 plus IL-18 ( Figure 1 cytokine preactivation, we observed a moderate fraction of NK cells producing IFN-g in response to IL-2 alone, indicating that prior cytokine activation primes an enhanced IFN-g response to individual cytokines (Supplemental Figure 3 ) [20] . Similarly, a modest fraction of preactivated NK cells produce IFN-g in response to IL-12 alone, again due to the initial preactivation (0 pM IL-2, Figure 3C ). When IL-2 and IL-12 were combined, concentrations of 10 or 100 pM IL-2 were able to significantly costimulate IFN-g production in cytokine-preactivated NK cells. Concentrations above 100 pM failed to further increase IFN-g production, suggesting that additional signaling via intermediate affinity IL-2Rbg Significance was calculated by ANOVA.
was not required for maximal IFN-g in this setting. Control NK cells that were not preactivated with cytokines but were cultured in medium alone (ie, 72 hours in medium only) excluded trypan blue and 7-AAD but failed to produce IFN-g, even in response to established costimulatory conditions in resting CD56 dim NK cells (eg, 1 nM IL-2 plus IL-12) [31] , likely due to prolonged growth factor starvation (data not shown). Therefore, we cultured NK cells in low-dose IL-15 (1 ng/mL), which preserves the functionality of these cells but does not induce CD25 expression ( Figure 1B,C) . Low-dose IL15eactivated cells did not produce increased IFN-g with addition of IL-12 and IL-2, with the exception of 1nM IL-2 ( Figure 3C ). Thus, low concentrations of IL-2 stimulate and costimulate (in cooperation with IL-12) IFN-g production by combined cytokine-preactivated NK cells. We next evaluated the absolute requirement for CD25 and the high-affinity IL-2Rabg for these IL-2 effects.
IFN-g Production in Response to Picomolar
Concentrations of IL-2 Requires CD25 and the High-affinity IL-2Rabg Selective responsiveness to 10 to 100 pM IL-2 suggests action through the high-affinity IL-2Rabg. Furthermore, increased CD25 induction mediated by IL-15þIL-18 versus IL-12þIL-18 enhanced IL-2ecostimulated IFN-g production (mean 53% versus 32%, P < .05), and populations that expressed more CD25 per cell also produced more IFN-g ( Figure 3B ). However, to definitively establish the requirement for CD25 and high-affinity binding, we used a blocking anti-CD25 mAb. This approach selectively blocks the formation of the high-affinity IL-2Rabg because CD25 is not available to the complex, but it allows stimulation via the intermediate-affinity IL-2Rbg. The enhanced IFN-g production in response to 10 or 100 pM IL-2 by cytokinepreactivated NK cells was abrogated by preincubation with an anti-CD25 mAb ( Figure 3D ). In contrast, 1 nM IL-2 costimulated IFN-g production regardless of CD25 blockade. Collectively, these data indicate that picomolar concentrations of IL-2, signaling through an induced IL-2Rabg, stimulate enhanced IFN-g in preactivated NK cells.
Picomolar Concentrations of IL-2 Act via IL-2Rabg to Augment Cytotoxicity by Cytokine-Preactivated NK Cells
Resting CD56 dim NK cells mediate cytotoxicity when triggered by the appropriate target cell [1, 32] . We hypothesized that similar to the IFN-g results, picomolar concentrations of IL-2 would augment preactivated NK cell cytotoxicity. was being utilized at this IL-2 concentration. In each preactivation condition, the observed killing was dependent on the effector to target ratio, as expected ( Figure 4D ,E and Supplemental Figure 4 ).
Low Concentrations of IL-2 Facilitate Cytokine-activated NK Cell Proliferation via the IL-2Rabg
T cell secretion of IL-2 acts in an autocrine or paracrine capacity to induce activated T cell proliferation [23] . Additionally, activated mouse NK cells, either in the context of in vivo viral infection or in vitro cytokine stimulation, undergo substantial proliferation [4, 33] Figure 5A ). However, with IL-2 added at 10 pM or greater, CD56 dim NK cells were induced to proliferate in a dose-dependent manner ( Figure 5A-C) . Furthermore, when cells were precultured with an anti-CD25eblocking antibody, the proliferation induced by low-dose IL-2 (10 to 100 pM) was abrogated ( Figure 5B,C) . We observed substantial donor-dependent variability in the degree of proliferation by CD56 dim NK cells as demonstrated in Figure 5B and C, presumably due to reported differences in the proliferative capacity of human NK subsets [37] [38] [39] . However, all donors displayed a significant enhancement in proliferation with !10 pM IL-2 stimulation, as well as abrogation of this signaling after CD25 blockade.
IL-2 Supports Cytokine-Preactivated CIML NK Cells in vivo in NSG Mice
Preactivation of human NK cells with IL-12, IL-15, and IL-18 for 16 hours followed by prolonged culture in vitro with IL-15 for survival results in CIML NK cells. Based on the induction of a functional IL-2Rabg on preactivated NK cells, we hypothesized that rhIL-2 would selectively support cytokinepreactivated (IL-12, IL-15, IL-18) compared with control-(IL-15 only) activated NK cells in vivo. Cytokine-preactivated or control NK cells were generated from the same donor and, after extensive washing, were transferred into NSG mice, and rhIL-2 was administered every other day. After 1 week, mice were analyzed for human NK cell numbers and evaluated for CIML NK cell recall responses. Cytokine-preactivated NK cells had significantly improved engraftment in NSG mice in this system, compared with control (IL-15) NK cells ( Figure 6 ). Both CD56 bright and CD56 dim NK cells were identified, and enhanced recall functionality to cytokine or tumor targetebased restimulation by CIML NK cells was also evident ex vivo. These data suggest that administration of rhIL-2 after adoptive transfer of IL-12, IL-15, and IL-18epreactivated NK cells is a novel approach to administer and support functionenabled NK cells as adoptive immunotherapy for patients with hematologic malignancies. Significance was assessed by 2-way ANOVA.
cells peaking approximately 3.5 days after MCMV infection. In vitro, NK cells within bulk murine splenocytes were induced to express CD25 after 24 hours by the combination of IL-12 plus IL-18, which absolutely required IL-12-induced STAT4 signals [43] . Thus, we suspect that during human responses to viruses and potentially other pathogens, IL-12, IL-15, and IL-18 are produced, and CD56 dim NK cells are induced to express CD25 (Supplemental Figure 5) . Mouse splenocytes containing adoptively transferred human NK cells were evaluated for a recall IFN-g response after IL-12þIL-15 restimulation, demonstrating that CIML NK cells exhibit preserved, enhanced functionality in this xenograft model. Significance was assessed by t-test, with *P < .05, **P < .01, and ***P < .001.
12þIL-15þIL-18), return to a resting baseline state, and then exhibit enhanced functional responses to a wide variety of restimulation triggers, including cytokines, activating NK cell receptors, or tumor cells. This was first described in mouse systems [16, 45] , and human NK cells were also found to exhibit similar CIML responses [20] . In addition, Ly49H-mediated "memory" NK cell function in the context of MCMV infection was found to depend on early proinflammatory cytokine signals [17] . For human NK cells, it is noteworthy that the same cytokine combinations of IL-12 plus IL-18 or IL-15 plus IL-18 that preactivate memory-like NK functionality are also the optimal cytokine inducers of CD25 expression. Although human CIML NK cells were supported with IL-15 in vitro after preactivation [20] , low concentrations of IL-2 may also have a role in supporting these memory-like NK cell functions, either endogenously or exogenously [21] . In addition, mouse IL-12, IL-15, and IL-18epreactivated NK cells were also recently shown to effectively clear mouse tumor cell line challenges in vivo [21] . After transfer into irradiated syngeneic mice, NK cells were found to require CD4 þ T cell derived IL-2 in vivo to effectively eliminate lymphoma and melanoma cell line challenges. Both murine and human NK cells were also shown to express CD25 immediately after IL-12, IL-15, and IL-18 activation, which is consistent with our findings in human NK cell subsets [21] . Thus, both human and mouse NK cells can be induced to express CD25 and a highaffinity IL-2Rabg, which may be important to support NK cell functional competency after viral infection or after exogenous IL-12, IL-15, and IL-18 preactivation. What are the clinical implications of peripheral blood NK cell acquisition of a functional high-affinity IL-2Rabg? Allogeneic NK cell therapy has evidence of antileukemic activity in clinical trials in acute myelogenous leukemia patients [46] . Low-dose or ultra-lowedose IL-2 therapy has been shown to expand CD56 bright NK cells selectively over CD56 dim NK cells in patients with HIV infection or cancer [47, 48] , most likely due to lack of the high-affinity IL-2Rabg on CD56 dim NK cells that promotes survival in the resting state [49] . As CD56 dim NK cells represent 80% to 95% of the mature peripheral blood NK population, adoptive transfer of NK cells preactivated with combinations of IL-12, IL-15, and IL-18, followed by lowdose IL-2 therapy in vivo, may be a useful strategy to further enhance antitumor and/or antiviral NK cell responses. Such an approach would include strategies to limit regulatory T cell numbers or function. In summary, NK cells that are preactivated with combinations of IL-12, IL-15, and IL-18 are induced to express CD25 and a high-affinity IL-2Rabg, which persists in CIML NK cells. This results in an acquired ability of all peripheral blood NK cells to proliferate, kill tumor targets, and produce IFN-g in response to picomolar concentrations of IL-2. IL-2 supports CIML NK cells in vivo in xenograft models. Thus, our findings provide a rationale for low-dose IL-2 therapy to enhance expansion and NK cell function after IL-12, IL-15, and IL18epreactivated NK cell adoptive transfer as immunotherapy for cancer patients.
